Sanofi’s Shantha Deal Fails to Bring Viehbacher a Sales Boost - BusinessWeek: "Sanofi-Aventis SA’s 440-million-euro ($602 million) acquisition of Indian vaccine maker Shantha Biotechnics Ltd. failed to live up to analyst forecasts after manufacturing woes wiped out $340 million of sales.
The World Health Organization on July 28 dropped Shantha’s Shan5 vaccine for five childhood diseases from its list of shots that are approved for sale to agencies such as the United Nations Children’s Fund after white sediment was found in some vials. The suspension has cost France’s biggest drugmaker the $340 million in sales it planned to book from 2010 to 2012 from a contract with Unicef, said Pascal Barollier, a spokesman for the company’s Sanofi Pasteur vaccine unit in Lyon.
- Sent using Google Toolbar"
No comments:
Post a Comment